Edition:
United States

Exact Sciences Corp (EXAS.OQ)

EXAS.OQ on NASDAQ Stock Exchange Capital Market

67.11USD
17 Dec 2018
Change (% chg)

-- (--)
Prev Close
$67.11
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
601,654
52-wk High
$82.83
52-wk Low
$37.39

Latest Key Developments (Source: Significant Developments)

Jana Partners Dissolves Share Stake In Alphabet, Facebook; Cuts In Microsoft, GM
Wednesday, 14 Nov 2018 10:37am EST 

Nov 14 (Reuters) - :JANA PARTNERS LLC DISSOLVES SHARE STAKE OF CLASS A CAPITAL STOCK IN ALPHABET INC - SEC FILING.JANA PARTNERS LLC DISSOLVES SHARE STAKE IN FACEBOOK INC.JANA PARTNERS LLC CUTS SOLE SHARE STAKE IN MICROSOFT CORP BY 55.0 PERCENT TO 334,359 SHARES.JANA PARTNERS LLC CUTS SOLE SHARE STAKE IN GENERAL MOTORS CO BY 56 PERCENT TO 280,560 SHARES.JANA PARTNERS LLC CUTS SOLE SHARE STAKE IN ALIBABA GROUP HOLDING LTD BY 20.8 PERCENT TO 348,055 SPONSORED ADS.JANA PARTNERS LLC TAKES SOLE SHARE STAKE OF 65,000 SHARES IN UNITED STATES STEEL CORP.JANA PARTNERS LLC TAKES SOLE SHARE STAKE OF 4.6 MILLION SHARES IN FALCON MINERALS CORP.JANA PARTNERS LLC TAKES SOLE SHARE STAKE OF 1.2 MILLION SHARES IN EXACT SCIENCES CORP.JANA PARTNERS LLC DISSOLVES SOLE SHARE STAKE IN AUTOMATIC DATA PROCESSING INC.JANA PARTNERS LLC CUTS SOLE SHARE STAKE IN AGILENT TECHNOLOGIES INC BY 33.6 PERCENT TO 810,314 SHARES.JANA PARTNERS LLC: CHANGE IN HOLDINGS ARE AS OF SEPTEMBER 30, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF JUNE 30, 2018.  Full Article

Cologuard Revenue Increased 63 Percent To $118 Million In Q3
Tuesday, 30 Oct 2018 04:05pm EDT 

Oct 30 (Reuters) - Exact Sciences Corp ::COLOGUARD® REVENUE INCREASED 63 PERCENT TO $118 MILLION, AND COLOGUARD TEST VOLUME GREW 49 PERCENT TO 241,000 DURING THIRD QUARTER.Q3 LOSS PER SHARE $0.37.Q3 REVENUE $118.3 MILLION VERSUS I/B/E/S VIEW $109.3 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.42 -- THOMSON REUTERS I/B/E/S.ANTICIPATES REVENUE OF $435-$440 MILLION FOR 2018.FY2018 REVENUE VIEW $428.6 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Exact Sciences Strengthens Pipeline Capabilities With Acquisition Of Biomatrica
Thursday, 18 Oct 2018 07:00am EDT 

Oct 18 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES STRENGTHENS PIPELINE CAPABILITIES WITH ACQUISITION OF BIOMATRICA, A LEADING PROVIDER OF BIOLOGICAL SAMPLE PRESERVATION TECHNOLOGY.EXACT SCIENCES CORP - FINANCIAL TERMS OF TRANSACTION ARE NOT BEING DISCLOSED..EXACT SCIENCES CORP - BIOMATRICA WILL REMAIN BASED IN SAN DIEGO.EXACT SCIENCES - INTENDS TO USE BIOMATRICA'S PROPRIETARY TECHNOLOGY TO SUPPORT ONGOING & FUTURE DEVELOPMENT OF ITS OWN BLOOD-BASED CANCER DETECTION TESTS.  Full Article

Exact Sciences Says Enter Agreement Through 2021 With Pfizer To Co-Promote Cologuard
Wednesday, 22 Aug 2018 12:08pm EDT 

Aug 22 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES SAYS CO, PFIZER ENTER INTO AGREEMENT THROUGH 2021 TO CO-PROMOTE COLOGUARD, A STOOL DNA SCREENING TEST FOR COLORECTAL CANCER.EXACT SCIENCES SAYS AS PER AGREEMENT, PFIZER WILL CO-PROMOTE COLOGUARD WITH CO BEGINNING IN Q4 2018.EXACT SCIENCES SAYS AS PER AGREEMENT, CO WILL MAINTAIN RESPONSIBILITY FOR ALL ASPECTS OF MANUFACTURING & LABORATORY OPERATIONS OF COLOGUARD.EXACT SCIENCES SAYS AS PER AGREEMENT, PFIZER WILL SHARE GROSS PROFITS & MARKETING EXPENSES EQUALLY ABOVE AN AGREED UPON BASELINE.  Full Article

Exact Sciences reports Q1 Loss Per Share of $0.33
Thursday, 26 Apr 2018 04:05pm EDT 

April 26 (Reuters) - Exact Sciences Corp ::Q1 LOSS PER SHARE $0.33.Q1 REVENUE $90.3 MILLION VERSUS I/B/E/S VIEW $86.9 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 REVENUE $420 MILLION TO $430 MILLION.FOR Q2, COMPANY ANTICIPATES COMPLETING 220,000-230,000 COLOGUARD TESTS.  Full Article

Exact Sciences Q4 Loss Per Share $0.18
Thursday, 22 Feb 2018 04:05pm EST 

Feb 22 (Reuters) - Exact Sciences Corp ::COLOGUARD® REVENUE INCREASED 168 PERCENT TO $266 MILLION.Q4 LOSS PER SHARE $0.18.Q4 REVENUE ROSE 148 PERCENT TO $87.4 MILLION.SEES FY 2018 REVENUE $420 MILLION TO $430 MILLION.ANTICIPATES COMPLETED COLOGUARD TEST VOLUME OF 900,000-920,000 TESTS DURING 2018..Q4 EARNINGS PER SHARE VIEW $-0.24, REVENUE VIEW $85.7 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Exact Sciences Offers $500 Mln Convertible Senior Notes Due 2025
Thursday, 11 Jan 2018 04:01pm EST 

Jan 11 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES ANNOUNCES OFFERING OF $500 MILLION CONVERTIBLE SENIOR NOTES DUE 2025.  Full Article

Exact Sciences Says "Comfortable" With Current 2018 Consensus Revenue Estimate Of Around $417 Mln
Wednesday, 10 Jan 2018 08:09am EST 

Jan 10 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES CORP SAYS "COMFORTABLE" WITH CURRENT 2018 CONSENSUS REVENUE ESTIMATE OF AROUND $417 MILLION.  Full Article

Exact Sciences Says On Dec. 15, Co, Unit Entered Loan, Security Agreement For 24-Month Secured Revolving Credit Facility For Up To $15.0 Mln
Monday, 18 Dec 2017 09:11am EST 

Dec 18 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES - ON DEC. 15, CO, UNIT ENTERED LOAN, SECURITY AGREEMENT FOR 24-MONTH SECURED REVOLVING CREDIT FACILITY FOR UP TO $15.0 MILLION - SEC FILING.EXACT SCIENCES - ON DEC. 15, UNIT ENTERED LOAN AGREEMENT FOR A NON-REVOLVING CONSTRUCTION LOAN OF UP TO $25.6 MILLION.  Full Article

Exact Sciences reports qtrly loss per share of $0.23
Monday, 30 Oct 2017 04:05pm EDT 

Oct 30 (Reuters) - Exact Sciences Corp ::Exact Sciences Corp qtrly loss per share $0.23; qtrly revenue $72.6 million, up 158 percent.Exact Sciences Corp sees 2017 revenue of $254 million to $257 million.  Full Article

Exact Sciences surges after marketing deal with Pfizer for cancer test

Exact Sciences Corp's shares shot up as much as 26 percent on Wednesday after the company said Pfizer Inc would share marketing expenses and co-promote the company's stool screening test for colorectal cancer.